Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.40, $0.15 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $3.7 billion versus the consensus estimate of $3.61 billion.

GUIDANCE:

Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of $2.39. Teva Pharma sees FY2023 revenue of $14.8-15.4 billion, versus the consensus of $15.04 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.